Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 55.55 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ultragenyx Pharmaceu < Previous 1 2 3 4 5 6 7 8 Next > Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M July 14, 2022 Via Benzinga What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical July 01, 2022 Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: Via Benzinga Netflix To $210? Here's The Biggest Price Target Changes For Friday July 01, 2022 Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading. Via Benzinga Expert Ratings for Ultragenyx Pharmaceutical May 24, 2022 Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Via Benzinga Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years May 23, 2022 Via Benzinga The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate May 19, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Earnings Scheduled For February 10, 2022 February 10, 2022 Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. Via Benzinga Earnings Scheduled For November 2, 2021 November 02, 2021 Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... Via Benzinga The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation May 17, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More May 16, 2022 Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... Via Benzinga Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know May 10, 2022 Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%... Via Benzinga What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical May 06, 2022 Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: Via Benzinga The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study May 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Ultragenyx Pharmaceutical's Earnings Outlook May 04, 2022 Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical March 16, 2022 Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 March 16, 2022 Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... Via Benzinga Where Ultragenyx Pharmaceutical Stands With Analysts March 16, 2022 Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Ultragenyx Pharmaceutical: Q4 Earnings Insights February 10, 2022 Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Via Benzinga The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly February 10, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More February 06, 2022 Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... Via Benzinga Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Transcript November 03, 2021 RARE earnings call for the period ending October 2, 2021. Via The Motley Fool Topics Earnings Exposures Financial The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US November 02, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... Via Benzinga Exposures COVID-19 Stocks That Hit 52-Week Lows On Wednesday January 19, 2022 During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... Via Benzinga The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline October 31, 2021 Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... Via Benzinga What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical September 30, 2021 Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 September 30, 2021 Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... Via Benzinga Ultragenyx Resumes Dosing Antisense Trial In Rare Neurogenetic Disorder September 27, 2021 The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) GTX-102 trial for... Via Benzinga Exposures Product Safety Return on Capital Employed Insights for Ultragenyx Pharmaceutical August 19, 2021 After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 August 19, 2021 Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ: Via Benzinga Return on Capital Employed Overview: Ultragenyx Pharmaceutical August 13, 2021 After pulling data from Benzinga Pro it seems like during Q2, Ultragenyx Pharmaceutical (NASDAQ:RARE) posted sales of $86.97 million. Earnings were up 22.33%, but Ultragenyx... Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.